Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765643333> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2765643333 endingPage "A555" @default.
- W2765643333 startingPage "A555" @default.
- W2765643333 abstract "Idiopathic Pulmonary Fibrosis (IPF) is a rare, progressive disease of unknown aetiology with a median survival of 3 years. To date, nintedanib and pirfenidone are the only antifibrotic agents indicated for the treatment of IPF in Western countries. The aim of this study is to conduct a systematic review of the literature on the cost-effectiveness of these two medicines. Search strings with “nintedanib”, “pirfenidone”, “cost-effectiveness”, “cost-utility”, “idiopathic pulmonary fibrosis” and “health technology assessment” terms were entered in PubMed, ISPOR presentations database, EMBASE, ScienceDirect, Cochrane CENTRAL, BIOSIS, Tufts CEA registry, the UK National Institute for Health Research Health Technology Assessment Database, Web of Science and Google. Relevant abstracts, publications and articles in English were collected from inception to June 2017. A total of 12 publications were included in the review. Five studies were conducted in the UK setting, 2 in Canada and Italy, 1 in France, Ireland and Spain. In 10 studies, the perspective was of the National Health Service. Ten studies used a Markov model while 1 other study used a microsimulation model. When compared to best supportive care (BSC), neither nintedanib nor pirfenidone had an incremental cost-effectiveness ratio inferior to €30,000 in any studies except in one which aimed to assess the impact of different models. Seven studies compared nintedanib to pirfenidone. Six of them showed economic dominance of nintedanib over pirfenidone (less costs, more quality-adjusted life years [QALY]), while one showed that pirfenidone was a cost-effective strategy (more QALYs but more costs) compared to nintedanib. Overall, the cost-effectiveness of IPF treatments has been well studied. Nintedanib and pirfenidone have demonstrated important clinical benefits for patients with IPF. Due the lack of alternative treatment, nintedanib and pirfenidone are rarely cost-effective versus BSC. When compared together, nintedanib dominates pirfenidone in most analyses (less costs, more QALYs)." @default.
- W2765643333 created "2017-11-10" @default.
- W2765643333 creator A5014251260 @default.
- W2765643333 creator A5024442591 @default.
- W2765643333 creator A5034955815 @default.
- W2765643333 creator A5073669489 @default.
- W2765643333 creator A5078619309 @default.
- W2765643333 date "2017-10-01" @default.
- W2765643333 modified "2023-09-26" @default.
- W2765643333 title "Systematic Review of The Cost-Effectiveness of Medicines For The Treatment of Idiopathic Pulmonary Fibrosis" @default.
- W2765643333 doi "https://doi.org/10.1016/j.jval.2017.08.889" @default.
- W2765643333 hasPublicationYear "2017" @default.
- W2765643333 type Work @default.
- W2765643333 sameAs 2765643333 @default.
- W2765643333 citedByCount "1" @default.
- W2765643333 countsByYear W27656433332022 @default.
- W2765643333 crossrefType "journal-article" @default.
- W2765643333 hasAuthorship W2765643333A5014251260 @default.
- W2765643333 hasAuthorship W2765643333A5024442591 @default.
- W2765643333 hasAuthorship W2765643333A5034955815 @default.
- W2765643333 hasAuthorship W2765643333A5073669489 @default.
- W2765643333 hasAuthorship W2765643333A5078619309 @default.
- W2765643333 hasBestOaLocation W27656433331 @default.
- W2765643333 hasConcept C112930515 @default.
- W2765643333 hasConcept C126322002 @default.
- W2765643333 hasConcept C138816342 @default.
- W2765643333 hasConcept C142724271 @default.
- W2765643333 hasConcept C177713679 @default.
- W2765643333 hasConcept C2776125615 @default.
- W2765643333 hasConcept C2776738588 @default.
- W2765643333 hasConcept C2777714996 @default.
- W2765643333 hasConcept C2778341716 @default.
- W2765643333 hasConcept C2779832356 @default.
- W2765643333 hasConcept C2780171596 @default.
- W2765643333 hasConcept C3019080777 @default.
- W2765643333 hasConcept C512399662 @default.
- W2765643333 hasConcept C524218345 @default.
- W2765643333 hasConcept C64332521 @default.
- W2765643333 hasConcept C71924100 @default.
- W2765643333 hasConceptScore W2765643333C112930515 @default.
- W2765643333 hasConceptScore W2765643333C126322002 @default.
- W2765643333 hasConceptScore W2765643333C138816342 @default.
- W2765643333 hasConceptScore W2765643333C142724271 @default.
- W2765643333 hasConceptScore W2765643333C177713679 @default.
- W2765643333 hasConceptScore W2765643333C2776125615 @default.
- W2765643333 hasConceptScore W2765643333C2776738588 @default.
- W2765643333 hasConceptScore W2765643333C2777714996 @default.
- W2765643333 hasConceptScore W2765643333C2778341716 @default.
- W2765643333 hasConceptScore W2765643333C2779832356 @default.
- W2765643333 hasConceptScore W2765643333C2780171596 @default.
- W2765643333 hasConceptScore W2765643333C3019080777 @default.
- W2765643333 hasConceptScore W2765643333C512399662 @default.
- W2765643333 hasConceptScore W2765643333C524218345 @default.
- W2765643333 hasConceptScore W2765643333C64332521 @default.
- W2765643333 hasConceptScore W2765643333C71924100 @default.
- W2765643333 hasIssue "9" @default.
- W2765643333 hasLocation W27656433331 @default.
- W2765643333 hasOpenAccess W2765643333 @default.
- W2765643333 hasPrimaryLocation W27656433331 @default.
- W2765643333 hasRelatedWork W1982007038 @default.
- W2765643333 hasRelatedWork W2016319444 @default.
- W2765643333 hasRelatedWork W2087783506 @default.
- W2765643333 hasRelatedWork W2137780073 @default.
- W2765643333 hasRelatedWork W2565473422 @default.
- W2765643333 hasRelatedWork W2896769567 @default.
- W2765643333 hasRelatedWork W2955182211 @default.
- W2765643333 hasRelatedWork W3045038100 @default.
- W2765643333 hasRelatedWork W4205836605 @default.
- W2765643333 hasRelatedWork W4220772094 @default.
- W2765643333 hasVolume "20" @default.
- W2765643333 isParatext "false" @default.
- W2765643333 isRetracted "false" @default.
- W2765643333 magId "2765643333" @default.
- W2765643333 workType "article" @default.